April 23, 2021 Drug Utilization Review Board (DURB) Agenda
»
1. Call to order
1. Call to order
»
2. Approval of minutes from January 22, 2021 (vote required)
2. Approval of minutes from January 22, 2021 (vote required)
»
3. Public comment on the drug classes to be reviewed for the Medicaid Preferred Drug List (PDL): » - a. Anti-allergens, oral b. Antibiotics, inhaled c. Anticoagulants d. Antidepressants, other e. Antidepressants, selective serotonin reuptake inhibitors (SSRIs) f. Antidepressants, tricyclic g. Antihyperuricemics h. Antivirals, oral i. Anxiolytics j. Benign prostatic hyperplasia treatments k. Beta-blockers l. Bile salts m. Bronchodilators, beta-agonist n. Chronic obstructive pulmonary disease agents o. Cough and cold p. Erythropoiesis stimulating proteins q. Glucocorticoids, inhaled r. Hemophilia treatment s. Hereditary angioedema (HAE) treatments t. Hypoglycemics, incretin mimetics/enhancers u. Immune globulins, intravenous v. Immunomodulators, asthma w. Lincosamides/oxazolidinones/streptogramins x. Lipotropics, other y. Lipotropics, statins z. Multiple sclerosis agents aa. aa.Pancreatic enzymes ab. bb.Pediatric vitamin preparations ac. cc.Prenatal vitamins ad. dd.Pulmonary arterial hypertension agents, oral and inhaled ae. ee.Sedative hypnotics af. ff.Sickle cell anemia treatments ag. gg.Thrombopoiesis stimulating proteins ah. hh.Urea cycle disorder, oral
3. Public comment on the drug classes to be reviewed for the Medicaid Preferred Drug List (PDL): »
a. Anti-allergens, oral b. Antibiotics, inhaled
c. Anticoagulants
d. Antidepressants, other
e. Antidepressants, selective serotonin reuptake inhibitors (SSRIs)
f. Antidepressants, tricyclic
g. Antihyperuricemics
h. Antivirals, oral
i. Anxiolytics
j. Benign prostatic hyperplasia treatments
k. Beta-blockers
l. Bile salts
m. Bronchodilators, beta-agonist
n. Chronic obstructive pulmonary disease agents
o. Cough and cold
p. Erythropoiesis stimulating proteins
q. Glucocorticoids, inhaled
r. Hemophilia treatment
s. Hereditary angioedema (HAE) treatments
t. Hypoglycemics, incretin mimetics/enhancers
u. Immune globulins, intravenous
v. Immunomodulators, asthma
w. Lincosamides/oxazolidinones/streptogramins
x. Lipotropics, other
y. Lipotropics, statins
z. Multiple sclerosis agents
aa. aa.Pancreatic enzymes
ab. bb.Pediatric vitamin preparations
ac. cc.Prenatal vitamins
ad. dd.Pulmonary arterial hypertension agents, oral and inhaled
ae. ee.Sedative hypnotics
af. ff.Sickle cell anemia treatments
ag. gg.Thrombopoiesis stimulating proteins
ah. hh.Urea cycle disorder, oral
»
4. Public comment on new drugs to be reviewed for the Medicaid PDL: » - a. Dificid suspension (oral)/Antibiotics, gastrointestinal b. Nyvepria (subcutaneous)/Colony stimulating factors c. Ibupak kit (oral)/nonsteroidal anti-inflammatory drugs (NSAIDs) d. Venngel one kit (topical)/NSAIDs e. Pataday extra strength over the counter (ophthalmic)/ophthalmics for allergic conjunctivitis f. Eysuvis (ophthalmic)/ophthalmics, anti-inflammatory/immunomodulator g. Impeklo lotion (topical)/steroids, topical very high
4. Public comment on new drugs to be reviewed for the Medicaid PDL: »
a. Dificid suspension (oral)/Antibiotics, gastrointestinal b. Nyvepria (subcutaneous)/Colony stimulating factors
c. Ibupak kit (oral)/nonsteroidal anti-inflammatory drugs (NSAIDs)
d. Venngel one kit (topical)/NSAIDs
e. Pataday extra strength over the counter (ophthalmic)/ophthalmics for allergic conjunctivitis
f. Eysuvis (ophthalmic)/ophthalmics, anti-inflammatory/immunomodulator
g. Impeklo lotion (topical)/steroids, topical very high
»
5. Therapeutic and clinical drug reviews and updates: Magellan Medicaid Administration
5. Therapeutic and clinical drug reviews and updates: Magellan Medicaid Administration
»
6. Executive work session
6. Executive work session
»
1. Announcements of drugs recommended for the Medicaid PDL: Magellan Medicaid Administration (vote required)
1. Announcements of drugs recommended for the Medicaid PDL: Magellan Medicaid Administration (vote required)
»
2. Retrospective drug utilization review (DUR): Conduent, LLC » - a. Report on recent retrospective DUR interventions: i. Anticonvulsants drug use evaluation (DUE) ii. Comprehensive opioid management iii. Management of psychotropic drugs in youth b. Report on recent retrospective DUR intervention outcomes: i. Attention-deficit/hyperactivity disorder medication management ii. NSAIDs: DUE c. Retrospective DUR proposals: (vote required) i. Diabetes disease management ii. Dyslipidemia disease management iii. Influenza prevention: vaccination and education
2. Retrospective drug utilization review (DUR): Conduent, LLC »
a. Report on recent retrospective DUR interventions: i. Anticonvulsants drug use evaluation (DUE)
ii. Comprehensive opioid management
iii. Management of psychotropic drugs in youth
b. Report on recent retrospective DUR intervention outcomes:
i. Attention-deficit/hyperactivity disorder medication management
ii. NSAIDs: DUE
c. Retrospective DUR proposals: (vote required)
i. Diabetes disease management
ii. Dyslipidemia disease management
iii. Influenza prevention: vaccination and education
»
3. Prospective prior authorization proposals (clinical edits): KEPRO, LLC (vote required) » - a. Anxiolytic and sedative/hypnotics i. Criteria revision for sedative-hypnotics – adults ii. Add Belsomra and Dayvigo b. HAE agents i. Criteria revision ii. Add Orladeyo c. Hyperlipidemia agents i. Formerly protein convertase subtilisin/kexin type 9 agents ii. Add Juxtapid d. Multiple sclerosis agents - new criteria (safety checks)
3. Prospective prior authorization proposals (clinical edits): KEPRO, LLC (vote required) »
a. Anxiolytic and sedative/hypnotics i. Criteria revision for sedative-hypnotics – adults
ii. Add Belsomra and Dayvigo
b. HAE agents
i. Criteria revision
ii. Add Orladeyo
c. Hyperlipidemia agents
i. Formerly protein convertase subtilisin/kexin type 9 agents
ii. Add Juxtapid
d. Multiple sclerosis agents - new criteria (safety checks)
»
4. Retrospective drug use criteria for outpatient use in Vendor Drug Program:
The University of Texas at Austin College of Pharmacy (vote required) » - a. Aerosolized agents - metered-dose inhalers (MDIs): anticholinergic drugs b. Aerosolized agents - MDIs: anti-inflammatory drugs c. Aerosolized agents - MDIs: beta2 agonists (long-acting) d. Aerosolized agents - MDIs: beta2 agonists (short-acting) e. Antidepressant drugs – other f. Antidepressant drugs – SSRIs
4. Retrospective drug use criteria for outpatient use in Vendor Drug Program: The University of Texas at Austin College of Pharmacy (vote required) »
a. Aerosolized agents - metered-dose inhalers (MDIs): anticholinergic drugs b. Aerosolized agents - MDIs: anti-inflammatory drugs
c. Aerosolized agents - MDIs: beta2 agonists (long-acting)
d. Aerosolized agents - MDIs: beta2 agonists (short-acting)
e. Antidepressant drugs – other
f. Antidepressant drugs – SSRIs
»
Items 5 & 6 » - 5. Next meeting date: July 23, 2021 6. Adjourn
Items 5 & 6 »
5. Next meeting date: July 23, 2021 6. Adjourn
